EP1139751A4 - Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors - Google Patents

Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Info

Publication number
EP1139751A4
EP1139751A4 EP99967703A EP99967703A EP1139751A4 EP 1139751 A4 EP1139751 A4 EP 1139751A4 EP 99967703 A EP99967703 A EP 99967703A EP 99967703 A EP99967703 A EP 99967703A EP 1139751 A4 EP1139751 A4 EP 1139751A4
Authority
EP
European Patent Office
Prior art keywords
cardiomyocytes
vivo
efficient
stable
gene transfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99967703A
Other languages
German (de)
French (fr)
Other versions
EP1139751A1 (en
Inventor
Jeffrey M Leiden
Eric Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Development Corp filed Critical Arch Development Corp
Publication of EP1139751A1 publication Critical patent/EP1139751A1/en
Publication of EP1139751A4 publication Critical patent/EP1139751A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99967703A 1998-12-28 1999-12-28 Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors Ceased EP1139751A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11392398P 1998-12-28 1998-12-28
US113923P 1998-12-28
PCT/US1999/031093 WO2000038518A1 (en) 1998-12-28 1999-12-28 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Publications (2)

Publication Number Publication Date
EP1139751A1 EP1139751A1 (en) 2001-10-10
EP1139751A4 true EP1139751A4 (en) 2003-03-19

Family

ID=22352321

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967703A Ceased EP1139751A4 (en) 1998-12-28 1999-12-28 Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Country Status (5)

Country Link
EP (1) EP1139751A4 (en)
JP (1) JP2002533359A (en)
AU (1) AU763049B2 (en)
CA (1) CA2356551A1 (en)
WO (1) WO2000038518A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
KR20020049031A (en) * 1999-11-05 2002-06-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
ATE366319T1 (en) * 2000-08-17 2007-07-15 Keiya Ozawa ADENO-ASSOCIATED VIRUS-MEDIATED TRANSMISSION OF ANGIOGENESIS FACTORS
WO2002019966A2 (en) * 2000-09-06 2002-03-14 Johns Hopkins University Cardiac arrhythmia treatment methods
US20030022870A1 (en) * 2001-06-01 2003-01-30 Victor Dzau Methods of treating cardiac disorders
AU2003299204A1 (en) 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
JP5623740B2 (en) * 2006-07-25 2014-11-12 セラドン・コーポレーション Long-term antegrade epicardial coronary infusion of adeno-associated virus vector for gene therapy
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
EP2714709B1 (en) * 2011-05-26 2018-04-18 University of Washington Compositions for use in cell and gene based methods to improve cardiac function
EP3710043B1 (en) * 2017-11-16 2024-04-17 Universite d'Aix-Marseille Fgf10 for the treatment of heart diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792483A (en) * 1993-04-05 1998-08-11 Vickers, Inc. Injection molding machine with an electric drive

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012050A1 (en) * 1995-09-27 1997-04-03 The Rockefeller University Method for transferring genes to the heart using aav vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KESSLER P D ET AL: "SODIUM BUTYRATE GREATLY ENHANCES THE EFFICIENCY OF VIRAL TRANSDUCTION IN ADULT VENTRICULAR CARDIOMYOCYTES BY ADENO-ASSOCIATED VIRAL VECTORS", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 92, no. 8, 15 October 1995 (1995-10-15), pages 1408, XP000673503, ISSN: 0009-7322 *
See also references of WO0038518A1 *

Also Published As

Publication number Publication date
JP2002533359A (en) 2002-10-08
CA2356551A1 (en) 2000-07-06
WO2000038518A9 (en) 2002-04-11
WO2000038518A1 (en) 2000-07-06
AU763049B2 (en) 2003-07-10
AU2394200A (en) 2000-07-31
EP1139751A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
ZA958686B (en) Viral vectors and use in gene therapy
ZA989012B (en) Chlamydia protein gene sequence and uses thereof
EP1139751A4 (en) Efficient and stable $i(in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
IL133830A0 (en) Vertebrate tolomerase genes and proteins and uses thereof
IL195649A0 (en) Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same
IL132673A0 (en) Gene transfer with adenoviruses having modified fiber proteins
IL131209A0 (en) Recombinant haloaliphatic dehalogenases
GB9721909D0 (en) Gene delivery vectors and their uses
EP1165586A4 (en) TCL-1b GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS
ZA952563B (en) Recombinant viruses their preparation and their use in gene therapy
IL130168A0 (en) Genetically engineered cells comprising DNA expressing LAG-3 and their use
NZ314496A (en) Anti fas recombinant antibody protein, dna, vectors, host cells and preparation thereof
IL130608A0 (en) Novel nucleic and amino acid sequence
EP1186615A4 (en) Novel protein and dna thereof
EP1100545A4 (en) Regulated expression of recombinant proteins using rna viruses
HUP0002913A3 (en) Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP1064947A4 (en) In ovo vaccination of 1 type marek's disease virus
GB9700490D0 (en) Improvements in and relating to members
GB9918155D0 (en) Proteins and peptides
HK1049860A1 (en) Recombinant adenoviral vectors and their utillization in the treatment of liver cirrhosis
ZA952242B (en) Recombinant viruses their preparation and their use in gene therapy
IL149506A0 (en) Human heparanase-related polypeptide and nucleic acid
GB9916794D0 (en) In vitro virus reconstitution
EP1241256A4 (en) Novel gene and use thereof
IL146128A0 (en) Expression of heparin-binding protein in recombinant mammalian cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030204

17Q First examination report despatched

Effective date: 20031103

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090312